Essential Premium

Biotech Surge Sends Averill to the Top of February’s Market Winners

A rebound in life‑sciences stocks — and a breakout Veradermics IPO — helped Averill’s funds notch some of the sector’s strongest gains last month.

Ray Dalio: U.S. Risks a Major Geopolitical Setback if Iran Holds Hormuz

The retired founder of Bridgewater Associates compared the situation with what happened with Great Britain during the Suez Canal Crisis.

Sponsored

LP Financing Solutions: A Creative Alternative for LPs Looking to Generate Liquidity 

Seligman Bets Carvana’s High-Flying Stock Won’t Hold Up

The fund says Carvana’s valuation ignores weakening credit trends and opaque loan‑sales — and that insiders are quietly cashing out.

Related Content

From Deep Losses to Remarkable Gains: Biopharma’s Wildest Year in Recent Memory

Stephen Taub

Biopharma Funds Are in Sick Bay

Stephen Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram